Literature DB >> 10629141

Peripheral nerve amyloidosis in sural nerve biopsies: a clinicopathologic analysis of 13 cases.

B Rajani1, V Rajani, R A Prayson.   

Abstract

OBJECTIVE: Amyloidosis is a well-recognized but uncommon cause of peripheral neuropathy. Our objectives were to determine the overall prevalence of peripheral nerve amyloidosis in sural nerve biopsies and to evaluate the clinical and pathologic features of these lesions.
METHODS: All available histologic and ultrastructural materials on biopsy tissue from 13 cases of peripheral nerve amyloidosis were examined. Muscle biopsies performed at the same time as the nerve biopsy were reviewed when available. Clinical data were collected on all patients.
RESULTS: The prevalence of amyloidosis in sural nerve biopsies at our institution was 13 (1.2%) of 1098 cases over a 15.8-year period. These patients ranged in age from 41 to 82 years (median, 61 years) at initial presentation and included 10 men and 3 women. Presenting neuropathy symptoms were sensory in 6 of the 13 patients, motor in 2 cases, and mixed in 5 cases. Cardiac, renal, or gastrointestinal involvement was present in 7 of 13 cases. Two patients had myeloma and 7 had systemic autonomic symptoms. Two patients had probable familial amyloid polyneuropathy, and 1 patient demonstrated an alanine 60 point mutation. Amyloid, identified as amorphous eosinophilic extracellular deposits demonstrating apple green birefringence on Congo red stain or recognized by its characteristic fibrillar ultrastructure by electron microscopy, was identified in the endoneurium in 12 nerves, perineurium in 2 nerves, and epineurium in 9 nerves. Chronic inflammation was identified in 5 nerves. Axonal loss was recorded as mild (<25%) in 1 nerve, moderate (25% to 75%) in 8 nerves, and severe (>75%) in 4 nerves. Axonal degeneration predominated over demyelination in 8 of 10 cases that could be evaluated. Concomitant muscle biopsies contained amyloid deposits in 8 of 9 cases.
CONCLUSIONS: Amyloidosis is a rare (1.2% in our series) cause of peripheral neuropathy with a distinct microscopic and ultrastructural appearance. Just over half the patients in our study had visceral organ involvement and systemic autonomic symptoms. The peripheral neuropathy was associated with axonal degeneration and a moderate to severe axonal loss in the majority of cases. Amyloid deposition was present in 8 out of 9 muscle biopsies performed at the same time.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10629141     DOI: 10.5858/2000-124-0114-PNAISN

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  Stiff heart syndrome.

Authors:  Satya S Bhupathi; Sreelatha Chalasani; Roxann Rokey
Journal:  Clin Med Res       Date:  2010-09-17

2.  Primary amyloidosis presenting as upper limb multiple mononeuropathies.

Authors:  Jennifer A Tracy; Peter J Dyck; P James B Dyck
Journal:  Muscle Nerve       Date:  2010-05       Impact factor: 3.217

Review 3.  Amyloid in the cardiovascular system: a review.

Authors:  I Kholová; H W M Niessen
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

Review 4.  Amyloid in surgical pathology.

Authors:  Christoph Röcken; Knut Sletten
Journal:  Virchows Arch       Date:  2003-06-11       Impact factor: 4.064

5.  In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.

Authors:  Jennifer Kollmer; Ernst Hund; Benjamin Hornung; Ute Hegenbart; Stefan O Schönland; Christoph Kimmich; Arnt V Kristen; Jan Purrucker; Christoph Röcken; Sabine Heiland; Martin Bendszus; Mirko Pham
Journal:  Brain       Date:  2014-12-18       Impact factor: 13.501

6.  Rapid, automated nerve histomorphometry through open-source artificial intelligence.

Authors:  Simeon Christian Daeschler; Marie-Hélène Bourget; Dorsa Derakhshan; Vasudev Sharma; Stoyan Ivaylov Asenov; Tessa Gordon; Julien Cohen-Adad; Gregory Howard Borschel
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.